Report Type
Publication date
Published Date
  • Product Insights

    $100 | May 2023
    Product Insights

    UOL Group – Faber House Redevelopment – Central Singapore

    Equip yourself with the essential tools needed to make informed and profitable decisions with our UOL Group - Faber House Redevelopment - Central Singapore report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...

  • Company Profile

    $295 | March 2023
    Company Profile

    Aceragen Inc – Company Profile

    Aceragen Inc (Acragen), formerly Idera Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company, which focuses on the discovery, strategic clinical development, and commercialization of therapeutic drug candidates for the treatment of cancer and rare diseases. It is developing ACG-801 and ACG-701. It intends to develop treatments for CF PEx and melioidosis through the development of ACG-701 and to treat Faber disease through the development of ACG-801. During FY2022, the company discontinued its development of tilsotolimod (IMO-2125). Aceragen is headquartered in Durham,...

    Add to Basket
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.